摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl 6-methyl-1,2,3-oxathiazinane-3-carboxylate 2,2-dioxide | 1311368-91-8

中文名称
——
中文别名
——
英文名称
tert-butyl 6-methyl-1,2,3-oxathiazinane-3-carboxylate 2,2-dioxide
英文别名
Tert-butyl 6-methyl-2,2-dioxo-1,2lambda6,3-oxathiazinane-3-carboxylate;tert-butyl 6-methyl-2,2-dioxooxathiazinane-3-carboxylate
tert-butyl 6-methyl-1,2,3-oxathiazinane-3-carboxylate 2,2-dioxide化学式
CAS
1311368-91-8
化学式
C9H17NO5S
mdl
——
分子量
251.304
InChiKey
CIFMHARJEMLUFC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    311.9±25.0 °C(Predicted)
  • 密度:
    1.242±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.89
  • 拓扑面积:
    81.3
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED INDOLE MCL-1 INHIBITORS<br/>[FR] INHIBITEURS DE INDOLE MCL-1 SUBSTITUÉS
    申请人:UNIV VANDERBILT
    公开号:WO2015148854A1
    公开(公告)日:2015-10-01
    The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
    本发明提供了一种抑制抗凋亡Bcl-2家族成员髓细胞白血病-1 (Mcl-1)蛋白活性的化合物。本发明还提供了用于治疗因Mcl-1蛋白过度表达或失调而表征的疾病和病况(例如癌症)的药物组合物以及使用化合物的方法。
  • SUBSTITUTED INDOLE MCL-1 INHIBITORS
    申请人:Vanderbilt University
    公开号:US20170174689A1
    公开(公告)日:2017-06-22
    The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
    本发明提供了一种抑制抗凋亡Bcl-2家族成员髓性细胞白血病-1(Mcl-1)蛋白活性的化合物。本发明还提供了药物组合物以及使用化合物治疗由于Mcl-1蛋白过度表达或失调而导致的疾病和病况(例如癌症)的方法。
  • HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE
    申请人:Boyer Stephen James
    公开号:US20130137680A1
    公开(公告)日:2013-05-30
    The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    本发明涉及公式(I)的化合物及其药学上可接受的盐,其中R1、R2、R3、R4、R5和n的定义如本文所述。本发明还涉及包含这些化合物的药物组合物,使用这些化合物治疗各种疾病和障碍的方法,制备这些化合物的过程以及用于这些过程的中间体。
  • Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core
    申请人:Boyer Stephen James
    公开号:US09073926B2
    公开(公告)日:2015-07-07
    The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    本发明涉及式(I)化合物及其药学上可接受的盐,其中R1、R2、R3、R4、R5和n的定义如本文所述。本发明还涉及包含这些化合物的制药组合物、使用这些化合物治疗各种疾病和障碍的方法、制备这些化合物的过程以及在这些过程中有用的中间体。
  • HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE
    申请人:Boyer Stephen James
    公开号:US20130109679A1
    公开(公告)日:2013-05-02
    Disclosed are novel compounds which inhibit RSK, methods of making such compounds and pharmaceutical compositions comprising such compounds. Also disclosed are methods of treating RSK2 regulated disorders using compounds of the invention.
    本发明揭示了一种新型化合物,可抑制RSK,制备这种化合物的方法以及包含这种化合物的药物组合物。本发明还揭示了使用本发明化合物治疗RSK2调节的疾病的方法。
查看更多